Insider Selling: Electromed, Inc. (NYSE:ELMD) Director Sells 8,640 Shares of Stock

Electromed, Inc. (NYSE:ELMD) Director Kathleen Skarvan sold 8,640 shares of the firm’s stock in a transaction dated Friday, February 14th. The stock was sold at an average price of $32.25, for a total transaction of $278,640.00. Following the sale, the director now owns 71,576 shares of the company’s stock, valued at $2,308,326. This trade represents a 10.77 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

Kathleen Skarvan also recently made the following trade(s):

• On Tuesday, February 18th, Kathleen Skarvan sold 38,954 shares of Electromed stock. The shares were sold at an average price of $29.28, for a total transaction of $1,140,573.12.

Electromed Stock Down 2.5 %

ELMD opened at $28.63 on Friday. The firm has a 50-day moving average price of $31.40 and a 200-day moving average price of $25.17. Electromed, Inc. has a twelve month low of $13.74 and a twelve month high of $35.56. The company has a market capitalization of $245.07 million, a price-to-earnings ratio of 38.17 and a beta of 0.33.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the business. Russell Investments Group Ltd. purchased a new stake in shares of Electromed during the fourth quarter worth $37,000. IFP Advisors Inc bought a new position in Electromed in the 4th quarter worth about $59,000. Quantbot Technologies LP purchased a new position in Electromed during the 4th quarter valued at about $99,000. Bank of America Corp DE increased its position in shares of Electromed by 179.2% during the fourth quarter. Bank of America Corp DE now owns 4,004 shares of the company’s stock valued at $118,000 after buying an additional 2,570 shares during the period. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Electromed in the fourth quarter worth about $119,000. 40.82% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on the company. B. Riley initiated coverage on Electromed in a research note on Thursday. They issued a “buy” rating and a $38.00 price objective on the stock. StockNews.com lowered Electromed from a “strong-buy” rating to a “buy” rating in a research note on Wednesday.

About Electromed

Electromed, Inc develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients of various ages in the United States and internationally. The company offers SmartVest airway clearance system for patients with compromised pulmonary functions, including bronchiectasis and cystic fibrosis, as well as neuromuscular conditions, such as cerebral palsy and amyotrophic lateral sclerosis; SmartVest SQL System; SmartVest Clearway System that consists of an inflatable therapy garment, a programmable air pulse generator, and a patented single-hose that delivers air pulses from the generator to the garment to create oscillatory pressure on the chest wall; and SmartVest Connect, a wireless technology that allows data connection between physicians and patients to track therapy performance and collaborate in treatment decisions.